ZA200408744B - Drugs for treating vascular diseases. - Google Patents
Drugs for treating vascular diseases. Download PDFInfo
- Publication number
- ZA200408744B ZA200408744B ZA200408744A ZA200408744A ZA200408744B ZA 200408744 B ZA200408744 B ZA 200408744B ZA 200408744 A ZA200408744 A ZA 200408744A ZA 200408744 A ZA200408744 A ZA 200408744A ZA 200408744 B ZA200408744 B ZA 200408744B
- Authority
- ZA
- South Africa
- Prior art keywords
- medicament
- retinoid
- active ingredient
- action
- intravascular
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 74
- 208000019553 vascular disease Diseases 0.000 title claims description 21
- 229940079593 drug Drugs 0.000 title description 7
- 239000000126 substance Substances 0.000 claims description 40
- 239000004480 active ingredient Substances 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 230000001028 anti-proliverative effect Effects 0.000 claims description 16
- 208000027418 Wounds and injury Diseases 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 15
- 208000014674 injury Diseases 0.000 claims description 15
- 208000034827 Neointima Diseases 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 230000000069 prophylactic effect Effects 0.000 claims description 12
- 238000005469 granulation Methods 0.000 claims description 10
- 230000003179 granulation Effects 0.000 claims description 10
- 210000004204 blood vessel Anatomy 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 8
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 7
- 208000037803 restenosis Diseases 0.000 claims description 7
- 239000005711 Benzoic acid Substances 0.000 claims description 6
- 235000010233 benzoic acid Nutrition 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 6
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 206010038563 Reocclusion Diseases 0.000 claims description 4
- 238000007887 coronary angioplasty Methods 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 12
- -1 for example Chemical compound 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- 239000002861 polymer material Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229930002330 retinoic acid Natural products 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 description 4
- 102100020680 Krueppel-like factor 5 Human genes 0.000 description 4
- WPYMKLBDIGXBTP-VQEHIDDOSA-N benzoic acid Chemical compound OC(=O)C1=CC=C[13CH]=C1 WPYMKLBDIGXBTP-VQEHIDDOSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 238000002608 intravascular ultrasound Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004231 tunica media Anatomy 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241001517988 Pachymenia Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- KHYBPSFKEHXSLX-UHFFFAOYSA-N iminotitanium Chemical compound [Ti]=N KHYBPSFKEHXSLX-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000001644 umbilical artery Anatomy 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002118729 | 2002-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200408744B true ZA200408744B (en) | 2005-11-10 |
Family
ID=29243537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200408744A ZA200408744B (en) | 2002-04-22 | 2003-04-22 | Drugs for treating vascular diseases. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050234130A1 (ko) |
| EP (1) | EP1500401A4 (ko) |
| JP (1) | JP4270549B2 (ko) |
| KR (1) | KR100995225B1 (ko) |
| CN (1) | CN100553677C (ko) |
| AU (1) | AU2003227454B2 (ko) |
| CA (1) | CA2482147A1 (ko) |
| HK (1) | HK1079993B (ko) |
| NZ (1) | NZ536493A (ko) |
| WO (1) | WO2003089005A1 (ko) |
| ZA (1) | ZA200408744B (ko) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070161105A1 (en) | 2003-03-20 | 2007-07-12 | Reasearch Foundation Itsuu Laboratory | Method of forming organ |
| EP1733722A4 (en) * | 2004-03-10 | 2010-07-14 | Res Found Itsuu Lab | MEMORY FIXING ACCELERATOR |
| WO2005099759A1 (ja) * | 2004-04-16 | 2005-10-27 | Institute Of Medicinal Molecular Design. Inc. | 動脈硬化症の予防及び／又は治療のための医薬 |
| EP1781672B1 (en) * | 2004-08-27 | 2010-10-06 | Cordis Corporation | Solvent free amorphous rapamycin |
| US20070049579A1 (en) * | 2005-03-04 | 2007-03-01 | Ryozo Nagai | Medicament having neovascularization promoting action |
| US20080275002A1 (en) * | 2005-03-08 | 2008-11-06 | Taiho Pharmaceutical Co., Ltd. | Method for Treatment of Hepatic Cancer |
| EP1930001A4 (en) | 2005-09-09 | 2010-07-21 | Kemphys Ltd | PHARMACEUTICAL AGENT FOR THE PREVENTION AND / OR TREATMENT OF THOROTIC DISEASES |
| WO2007049542A1 (ja) | 2005-10-24 | 2007-05-03 | Taiho Pharmaceutical Co., Ltd. | RAR-α作動薬の有効性の予測方法 |
| WO2007071605A1 (en) * | 2005-12-19 | 2007-06-28 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | The use of st1898 for the treatment of restenosis |
| WO2010000784A1 (en) * | 2008-07-03 | 2010-01-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treatment of restenosis |
| CN102143767B (zh) * | 2008-09-08 | 2014-07-02 | 独立行政法人物质.材料研究机构 | 包含高分子基质和低分子有机化合物的复合材料、及其制造方法 |
| US20130045277A1 (en) * | 2010-02-03 | 2013-02-21 | Tetsushi Taguchi | Biocompatible device |
| JP4899224B2 (ja) * | 2010-05-11 | 2012-03-21 | 春三 小林 | 動脈硬化改善剤 |
| JP2016518342A (ja) | 2013-03-15 | 2016-06-23 | アヴィセンナ・コスメティクス・エルエルシーAvisenna Cosmetics, Llc | 加齢の影響を軽減するための局所組成物 |
| JP6386713B2 (ja) * | 2013-10-03 | 2018-09-05 | 国立大学法人千葉大学 | 脳循環障害の予防剤および／または治療剤 |
| JP2015180247A (ja) * | 2014-03-03 | 2015-10-15 | 国立大学法人 岡山大学 | 薬剤放出層を有するインプラント |
| GR1008697B (el) * | 2014-12-05 | 2016-02-25 | Rontis Hellas Α.Ε.Β.Ε., | Συσκευη που εκλυει φαρμακευτικη ουσια |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994341A (en) * | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| NZ533467A (en) * | 1993-07-19 | 2006-02-24 | Angiotech Pharm Inc | Anti-angiogenic compositions and methods of use |
| FR2723315B1 (fr) * | 1994-08-02 | 1996-10-25 | Cird Galderma | Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes |
| FR2735371B1 (fr) * | 1995-06-19 | 1997-07-18 | Cird Galderma | Procede pour identifier des composes antagonistes des recepteurs rars |
| JPH10265381A (ja) * | 1997-03-24 | 1998-10-06 | Sankyo Co Ltd | 血管再狭窄予防剤 |
| JP2001522350A (ja) * | 1997-04-11 | 2001-11-13 | シドニー キメル キャンサー センター | 疾患におけるエンドセリン−１の過剰産生の阻害のためのレチノイド関連分子 |
| AU744475B2 (en) * | 1997-04-24 | 2002-02-28 | Bristol-Myers Squibb Company | Methods and compositions for use in modulating expression of matrix metalloproteinase genes |
| AU1052599A (en) * | 1997-11-12 | 1999-05-31 | Institute Of Medicinal Molecular Design. Inc. | Retinoid receptor agonists |
| WO2000010552A2 (en) * | 1998-08-24 | 2000-03-02 | Global Vascular Concepts, Inc. | Use of anti-angiogenic agents for inhibiting vessel wall injury |
| ATE365158T1 (de) * | 1999-04-28 | 2007-07-15 | Inst Med Molecular Design Inc | Pyrimidincarbonsäurederivate |
| ATE370738T1 (de) * | 1999-11-09 | 2007-09-15 | Pharmacia Corp | Verwendung von eplerenon zur behandlung von restenose |
| JP4754714B2 (ja) * | 2000-06-01 | 2011-08-24 | テルモ株式会社 | 管腔内留置物 |
| JP2002320629A (ja) * | 2001-04-26 | 2002-11-05 | Terumo Corp | 体内埋め込み医療材料および体内埋め込み医療器具 |
| JP2003093520A (ja) * | 2001-07-06 | 2003-04-02 | Terumo Corp | ステント |
| JP2003033439A (ja) * | 2001-07-24 | 2003-02-04 | Terumo Corp | コーティングステントおよびその製造方法 |
| US7500986B2 (en) * | 2002-07-11 | 2009-03-10 | Medtronic Vascular, Inc. | Expandable body having deployable microstructures and related methods |
| US20070049579A1 (en) * | 2005-03-04 | 2007-03-01 | Ryozo Nagai | Medicament having neovascularization promoting action |
-
2003
- 2003-04-22 CN CNB038091569A patent/CN100553677C/zh not_active Expired - Fee Related
- 2003-04-22 ZA ZA200408744A patent/ZA200408744B/en unknown
- 2003-04-22 JP JP2003585756A patent/JP4270549B2/ja not_active Expired - Fee Related
- 2003-04-22 KR KR1020047016886A patent/KR100995225B1/ko not_active IP Right Cessation
- 2003-04-22 US US10/511,274 patent/US20050234130A1/en not_active Abandoned
- 2003-04-22 WO PCT/JP2003/005084 patent/WO2003089005A1/ja active Application Filing
- 2003-04-22 CA CA002482147A patent/CA2482147A1/en not_active Abandoned
- 2003-04-22 NZ NZ536493A patent/NZ536493A/en not_active IP Right Cessation
- 2003-04-22 EP EP03717687A patent/EP1500401A4/en not_active Withdrawn
- 2003-04-22 AU AU2003227454A patent/AU2003227454B2/en not_active Ceased
-
2006
- 2006-01-04 HK HK06100107.4A patent/HK1079993B/zh not_active IP Right Cessation
-
2009
- 2009-03-27 US US12/412,678 patent/US20090253796A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR100995225B1 (ko) | 2010-11-17 |
| EP1500401A1 (en) | 2005-01-26 |
| CA2482147A1 (en) | 2003-10-30 |
| NZ536493A (en) | 2007-03-30 |
| US20090253796A1 (en) | 2009-10-08 |
| US20050234130A1 (en) | 2005-10-20 |
| AU2003227454A1 (en) | 2003-11-03 |
| CN1655816A (zh) | 2005-08-17 |
| JP4270549B2 (ja) | 2009-06-03 |
| JPWO2003089005A1 (ja) | 2005-08-25 |
| HK1079993B (zh) | 2010-03-19 |
| CN100553677C (zh) | 2009-10-28 |
| AU2003227454B2 (en) | 2009-07-30 |
| HK1079993A1 (en) | 2006-04-21 |
| KR20050023249A (ko) | 2005-03-09 |
| EP1500401A4 (en) | 2009-12-23 |
| WO2003089005A1 (fr) | 2003-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090253796A1 (en) | Method for treating vascular disease | |
| TW200800196A (en) | Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices | |
| MX2010007571A (es) | Endoprotesis eluyente con receptaculo de rapamicina. | |
| CN101365447A (zh) | 用于治疗再狭窄病变的含有纳米粒子的药物组合物 | |
| CN100377742C (zh) | 包含低分子量凝血酶抑制剂及其药物前体的药用制剂 | |
| US20040198827A1 (en) | Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases | |
| US20060013852A1 (en) | Use of organic compounds | |
| US20070254956A1 (en) | Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation | |
| CN106621003A (zh) | 一种药物球囊导管及其制备方法和应用 | |
| AU721632B2 (en) | Agent for preventing restenosis | |
| US20220184058A1 (en) | Pharmaceutical composition for treating aortic aneurysm | |
| US7229979B2 (en) | Hypoestoxides, derivatives and agonists thereof for use as stent-coating agents | |
| WO2012116997A1 (en) | TREATMENT OF ARTERIAL AGEING BY HMG CoA REDUCTASE INHIBITOR | |
| JP2003531170A (ja) | 抗高血圧剤および使用 | |
| MX2015002646A (es) | Otamixaban para uso en el tratamiento de sindrome coronario agudo sin elevacion de st en pacientes programados para ser sometidos a injerto de bypass de arteria coronaria. | |
| KR20090099671A (ko) | 혈관 재협착 치료 또는 예방용 조성물 | |
| JP2008179570A (ja) | 内臓癒着の予防及び／又は治療のための医薬 | |
| WO2001097798A1 (en) | Method for the prevention or reduction of cardiovascular events associated with coronary intervention | |
| JP2006506336A (ja) | 動静脈の移植不全の予防及び／または処置のためのキマーゼ阻害剤の使用 | |
| JP2005289818A (ja) | 動脈硬化抑制剤および治療剤 | |
| AU2002354837A1 (en) | Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases | |
| JP2004284957A (ja) | 血管平滑筋細胞増殖抑制剤 | |
| JPWO2009101684A1 (ja) | 内臓癒着の予防及び／又は治療のための医薬 |